Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist

Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the blood–brain barrier (BBB) permeant proteasome inhibitor marizomib in a panel of pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Boccellato, Chiara, Kolbe, Emily, Peters, Nathalie, Juric, Viktorija, Fullstone, Gavin, Verreault, Maïté, Idbaih, Ahmed, Lamfers, Martine L. M., Murphy, Brona M., Rehm, Markus
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225658/
https://ncbi.nlm.nih.gov/pubmed/34168123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-021-03927-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars